# US 2014/0194383 A1 · Monomers capable of dimerizing in an aqueous solution, and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194383 A1
- Document ID: US20140194383A1
- Status: Published application
- Kind: A1
- Application number: 14/110,056
- Filed: 2012-04-09
- Published: 2014-07-10
- Earliest claimed: 2011-04-07
- Assignees: Cornell University; Coferon, Inc.; Purdue Research Foundation
- Inventors: Francis Barany; Maneesh Pingle; Donald E. Bergstrom; Sarah F. Giardina; Lee Daniel Arnold
- Web page: https://patentgrep.com/patent/US20140194383A1

## CPC

- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07F 5/025: {Boronic and borinic acid compounds}
- C07F 5/04: Esters of boric acids
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

## Claims

### Claim 1

A therapeutic multimer compound formed from the multimerization in an aqueous media of a first monomer represented by:
X1—Y1—Z1 (Formula I)
and a second monomer represented by
X2—Y2—Z2 (Formula II),
wherein
X1 is a first ligand moiety capable of binding to a first target biomolecule;
Y1 is absent or is a connector moiety covalently bound to X1 and Z1;
Z1 is a first linker selected from the group consisting of:
a)
wherein
A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
A2, independently for each occurrence, is (a) absent; or (b) selected from the group consisting of —N—, acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic, provided that at least one of A1 and A2 is present; or
A1 and A2, together with the atoms to which they are attached, form a substituted or unsubstituted 4-8 membered cycloalkyl or heterocyclic ring;
A3 is selected from the group consisting of —NHR′, —SH, or —OH;
W is CR′ or N;
R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
m is 1-6;
represents a single or double bond; and
R1 is (a) absent; or (b) selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
Q1 is (a) absent; or (b) selected from the group consisting of substituted or unsubstituted aliphatic or substituted or unsubstituted heteroaliphatic; or
R1 and Q1 together with the atoms to which they are attached form a substituted or unsubstituted 4-8 membered cycloalkyl or heterocyclic ring;
b)
wherein
BB, independently for each occurrence, is a 4-8 membered cycloalkyl, heterocyclic, aryl, or heteroaryl moiety, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl moiety is optionally substituted with one or more groups represented by R2, wherein the two substituents comprising —OH have a 1, 2 or 1,3 configuration;
each R2 is independently selected from hydrogen, halogen, oxo, sulfonate, —NO2, —CN, —OH, —NH2, —SH, —COOH, —CON(R′)2, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, or two R2 together with the atoms to which they are attached form a fused substituted or unsubstituted 4-6 membered cycloalkyl or heterocyclic bicyclic ring system;
A1, independently for each occurrence, is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
R′ is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
c)
wherein
BB is a substituted or unsubstituted 5- or 6-membered cycloalkyl, heterocyclic, aryl, or heteroaryl moiety;
A3, independently for each occurrence, is selected from the group consisting of —NHR′, —OH, or —O—C1-4alkyl;
R3 and R4 are independently selected from the group consisting of H, C1-4alkyl, phenyl, or R3 and R4 taken together from a 3-6 membered ring;
R5 and R6 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halogen, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or R5 and R6 taken together form phenyl or a 4-6 membered heterocycle; and
R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
d)
wherein
A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
A3, independently for each occurrence, is selected from the group consisting of —NHR′ or —OH;
AR is a fused phenyl or 4-7 membered aromatic or partially aromatic heterocyclic ring, wherein AR is optionally substituted by oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; —S—C1-4alkyl; halogen; —OH; —CN; —COOH; —CONHR′; wherein the two hydroxyl moieties are ortho to each other;
R5 and R6 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; CONHR′; and
R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
e)
wherein
Q1 is selected from the group consisting of C1-4alkyl, alkylene, or a bond; C1-6cycloalkyl; a 5-6 membered heterocyclic ring; or phenyl;
Q2, independently for each occurrence, is selected from the group consisting of H, C1-4alkyl, alkylene, or a bond; C1-6cycloalkyl; a 5-6 membered heterocyclic ring; phenyl; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
A3, independently for each occurrence, is selected from the group consisting of —NH2 or —OH;
A4, independently for each occurrence, is selected from the group consisting of —NH—NH2; —NHOH, —NH—OR″, or —OH;
R″ is selected from the group consisting of H or C1-4alkyl; and
f)
wherein
A5 is selected from the group consisting of —OH, —NH2, —SH, —NHR″′;
R′″ is selected from C1-4alkyl optionally substituted with hydroxyl; —NH2; —OH; —O-phenyl; and C1-4alkoxy;
R5 and R6 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or R5 and R6 taken together may form a 5-6 membered ring;
wherein
X2 is a second ligand moiety capable of binding to a second target biomolecule;
Y2 is absent or is a connector moiety covalently bound to X2 and Z2; and
Z2 is a boronic acid or oxaborale moiety capable of binding with the Z1 moiety of Formula I to form the multimer; and
pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof.

### Claim 2

A first monomer capable of forming a biologically useful multimer when in contact with a second monomer in an aqueous media, wherein the first monomer is represented by the formula:
X1—Y1—Z1 (Formula I)
and pharmaceutically acceptable salts, stereoisomers, metabolites, and hydrates thereof, wherein
X1 is a first ligand moiety capable of binding to a first target biomolecule;
Y1 is absent or is a connector moiety covalently bound to X1 and Z1;
Z1 is a first linker selected from the group consisting of:
a)
wherein
A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
A2, independently for each occurrence, is (a) absent; or (b) selected from the group consisting of —N—, acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic, provided that at least one of A1 and A2 is present; or
A1 and A2, together with the atoms to which they are attached, form a substituted or unsubstituted 4-8 membered cycloalkyl or heterocyclic ring;
A3 is selected from the group consisting of —NHR′, —SH, or —OH;
W is CR′ or N;
R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
m is 1-6;
represents a single or double bond; and
R1 is (a) absent; or (b) selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
Q1 is (a) absent; or (b) selected from the group consisting of substituted or unsubstituted aliphatic or substituted or unsubstituted heteroaliphatic; or
R1 and Q1 together with the atoms to which they are attached form a substituted or unsubstituted 4-8 membered cycloalkyl or heterocyclic ring;
b)
wherein
BB, independently for each occurrence, is a 4-8 membered cycloalkyl, heterocyclic, aryl, or heteroaryl moiety, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl moiety is optionally substituted with one or more groups represented by R2, wherein the two substituents comprising —OH have a 1, 2 or 1,3 configuration;
each R2 is independently selected from hydrogen, halogen, oxo, sulfonate, —NO2, —CN, —OH, —NH2, —SH, —COOH, —CON(R′)2, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, or two R2 together with the atoms to which they are attached form a fused substituted or unsubstituted 4-6 membered cycloalkyl or heterocyclic bicyclic ring system;
A1, independently for each occurrence, is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
R′ is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
c)
wherein
BB is a substituted or unsubstituted 5- or 6-membered cycloalkyl, heterocyclic, aryl, or heteroaryl moiety;
A3, independently for each occurrence, is selected from the group consisting of —NHR′, —OH, or —O—C1-4alkyl;
R3 and R4 are independently selected from the group consisting of H, C1-4alkyl, phenyl, or R3 and R4 taken together from a 3-6 membered ring;
R5 and R6 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halogen, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or R5 and R6 taken together form phenyl or a 4-6 membered heterocycle; and
R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
d)
wherein
A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
A3, independently for each occurrence, is selected from the group consisting of —NHR′ or —OH;
AR is a fused phenyl or 4-7 membered aromatic or partially aromatic heterocyclic ring, wherein AR is optionally substituted by oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; —S—C1-4alkyl; halogen; —OH; —CN; —COOH; —CONHR′; wherein the two substituents comprising —OH are ortho to each other;
R5 and R6 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; CONHR′; and
R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
e)
wherein
Q1 is selected from the group consisting of C1-4alkyl, alkylene, or a bond; C1-6cycloalkyl; a 5-6 membered heterocyclic ring; or phenyl;
Q2, independently for each occurrence, is selected from the group consisting of H, C1-4alkyl, alkylene, or a bond; C1-6cycloalkyl; a 5-6 membered heterocyclic ring; phenyl; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
A3, independently for each occurrence, is selected from the group consisting of —NH2 or —OH;
A4, independently for each occurrence, is selected from the group consisting of —NH—NH2; —NHOH, —NH—OR″, or —OH;
R″ is selected from the group consisting of H or C1-4alkyl; and
f)
wherein
A5 is selected from the group consisting of —OH, —NH2, —SH, —NHR″′;
R′″ is selected from —NH2; —OH; —O-phenyl; and C1-4alkoxy;
R5 and R6 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or R5 and R6 taken together may form a 5-6 membered ring; and
the second monomer has a boronic acid or oxaborole moiety capable of binding with the Z1 moiety of Formula I to form the multimer.

### Claim 3 (depends on 2)

The first monomer of claim 2, wherein A1 is selected from the group consisting of C1-C3alkylene optionally substituted with one, two, or three halogens, or —C(O)—.

### Claim at position 4

4-8. (canceled)

### Claim 9 (depends on 2)

The first monomer of claim 2, wherein Z1 is selected from the group consisting of
wherein
X is selected from O, S, CH, NR′, or when X is NR′, N may be covalently bonded to Y of formula I;
R′ is selected from the group consisting of H, C1-4alkyl;
R5, R6, and R7 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or a mono- or bicyclic heterocyclic optionally substituted with amino, halo, hydroxyl, oxo, or cyano; and
AA is a 5-6 membered heterocyclic ring optionally substituted by C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′, or —S—C1-4alkyl.

### Claim 10 (depends on 9)

The first monomer of claim 9, wherein Z1 is

### Claim 11 (depends on 9)

The first monomer of claim 9, wherein Z1 is

### Claim 12 (depends on 9)

The first monomer of claim 9, wherein X is nitrogen.

### Claim 13 (depends on 9)

The first monomer of claim 9, wherein Z1 is

### Claim 14 (depends on 2)

The first monomer of claim 2, wherein Z1 is

### Claim 15 (depends on 14)

The first monomer of claim 14, wherein Z1 is

### Claim 16 (depends on 2)

The first monomer of claim 2, wherein Z1 is

### Claim at position 13

17-20. (canceled)

### Claim 21 (depends on 2)

The first monomer of claim 2, wherein Z1 is

### Claim 22 (depends on 2)

The first monomer of claim 2, wherein Z1 is

### Claim at position 16

23-24. (canceled)

### Claim 25 (depends on 2)

The first monomer of claim 2, wherein Z1 is

### Claim 26 (depends on 2)

The first monomer of claim 2, wherein Z1 is

### Claim 27 (depends on 2)

The first monomer of claim 2, wherein the first monomer forms a biologically useful dimer with a second monomer in vivo.

### Claim 28 (depends on 2)

The first monomer of claim 2, wherein the second monomer is X2—Y2—Z2 (Formula II), wherein Z2 is the boronic acid or oxaborole moiety, and wherein
X2 is a second ligand moiety capable of binding to a second target biomolecule; and
Y2 is absent or is a connector moiety covalently bound to X2 and Z2.

### Claim 29 (depends on 2)

The first monomer of claim 2, wherein X1 and X2 are the same.

### Claim 30 (depends on 2)

The first monomer of claim 2, wherein X1 and X2 are different.

### Claim 31 (depends on 2)

The first monomer of claim 2, wherein the first target biomolecule and the second target biomolecule are different.

### Claim 32 (depends on 2)

The first monomer of claim 2, wherein the first target biomolecule and the second target biomolecule are the same.

### Claim 33 (depends on 2)

The first monomer of claim 2, wherein the apparent IC50 of an essentially equimolar combination of the first monomer and the second monomer against the first target biomolecule and the second target biomolecule is at least about 3 to 10 fold lower than the lowest of the IC50 of the second monomer against the second target biomolecule or the IC50 of the first monomer against the first target biomolecule.

### Claim at position 26

34-35. (canceled)

### Claim 36 (depends on 2)

The first monomer of claim 2, wherein the aqueous fluid has a physiologically acceptable pH.

### Claim 37 (depends on 28)

The first monomer of claim 28, wherein Z2 of the second monomer is selected from the group consisting of:
wherein
R8 is selected from the group consisting of H, halogen, oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo or thio; C2-4alkenyl, C1-4alkoxy; —S—C1-4alkyl; —CN; —COOH; or —CONHR′;
A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
Q is selected from the group consisting of substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
AA, independently for each occurrence, is phenyl, aryl, or a 5-7 membered heterocyclic or heteroaryl ring having one, two, or three heteroatoms, wherein AA is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, C1-4alkyl optionally substituted by hydroxyl, amino, halogen, or thio; C2-4alkenyl; C1-4alkoxy; —S—C1-4alkyl; —CN; —NR2′″, wherein R′″ is independently selected from the group consisting of H and C1-4alkyl; —COOH; —CONHR′; or two substituents together with the atoms to which they are attached form a fused 4-6 membered cycloalkyl or heterocyclic bicyclic ring system; and
R′ is H or C1-4alkyl.

### Claim 38 (depends on 37)

The first monomer of claim 37, wherein R8 and the substituent comprising boronic acid are ortho to each other, and wherein R8 is —CH2NH2.

### Claim 39 (depends on 37)

The first monomer of claim 37, wherein Z2 of the second monomer is selected from the group consisting of

### Claim 40 (depends on 37)

The first monomer of claim 37, wherein Z2 of the second monomer is selected from the group consisting of:

### Claim 41 (depends on 27)

The first monomer of claim 27, wherein Z2 of the second monomer is selected from the group consisting of:
wherein
R8 is selected from the group consisting of H, halogen, oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo or thio; C2-4alkenyl, C1-4alkoxy; —S—C1-4alkyl; —CN; —COOH; or —CONHR′;
AA, independently for each occurrence, is a 5-7 membered heterocyclic ring having one, two, or three heteroatoms, or phenyl, wherein AA is optionally substituted by one, two, or three substituents selected from the group consisting of halo, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C2-4alkenyl, C1-4alkoxy; —S—C1-4alkyl; —CN; —NR2′″, wherein R′″ is independently selected from the group consisting of H and C1-4alkyl; —COOH; —CONHR′; or two substituents together with the atoms to which they are attached form a fused 4-6 membered cycloalkyl or heterocyclic bicyclic ring system; and
R′ is H or C1-4alkyl.

### Claim 42

(canceled)

### Claim 43 (depends on 27)

The first monomer of claim 27, wherein the first monomer and the second monomer form a dimer.

### Claim 44

(canceled)

### Claim 45 (depends on 2)

The first monomer of claim 2, wherein the target biomolecule is a protein.

### Claim 46

(canceled)

### Claim 47 (depends on 1)

A method of administering a pharmaceutically effective amount of a multimeric compound to a patient in need thereof, comprising administering to the patient thereof an amount of the first monomer of claim 1 and an amount of a boronic acid monomer in amounts effective such that the pharmaceutically effective amount of the resulting multimer is formed in vivo.

### Claim 48 (depends on 47)

The method of claim 47, wherein the multimer is a dimer.

### Claim 49

(canceled)

### Claim 50

A method of modulating two or more target biomolecule domains substantially simultaneously comprising:
contacting an aqueous composition comprising said biomolecule domains with a first monomer represented by:
X1—Y1—Z1 (Formula I)
and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof, wherein
X1 is a first ligand moiety capable of binding to a first target biomolecule domain; and
a second monomer represented by:
X2—Y2—Z2 (Formula II),
wherein
X2 is a ligand moiety capable of binding to a second target biomolecule domain;
wherein upon contact with the aqueous composition, said first monomer and said second monomer forms a dimer that binds to the first target biomolecule domain and the second target biomolecule domain.

### Claim at position 42

51-62. (canceled)
